Siwei (Shanghai) Biotechnology Co., Ltd.

Investors

Since our start in 2016, we have finished two financing rounds, the Angel round and Series A round, totaling over 100 million RMB. Our investors share our goal to become the first company in China to launch mRNA medicines and constantly support our effort.

About Us
- Our Story
- News Updates
- Contact Us
Platforms
- mRNA Synthesis Platform
- LPP Delivery Platform
- GMP Manufacturing
Pipeline
- Therapeutic Areas
- Development Candidates
Patients
- Clinical Trials
Partnering
- Investors
Join Us
- Opportunities